STOCK TITAN

Bioventus Inc. - BVS STOCK NEWS

Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.

Bioventus Inc. (NASDAQ: BVS) delivers innovative orthobiologic solutions that advance musculoskeletal healing through clinically proven therapies. This news hub provides investors and healthcare professionals with essential updates on the company’s progress in pain treatments, surgical technologies, and restorative care innovations.

Access real-time announcements including earnings reports, product launches, and strategic partnerships. Our curated collection features regulatory milestones, research developments, and acquisition updates that demonstrate Bioventus’ leadership in active healing technologies.

Discover how the company’s dual focus on internal R&D and targeted acquisitions strengthens its position across 90+ countries. Stay informed about evidence-based solutions addressing sports medicine, trauma care, and complex surgical needs through verified press releases and analyst-reviewed updates.

Bookmark this page for streamlined access to Bioventus’ latest advancements in orthobiologics. Check regularly for insights into how their global network and ethical practices shape the future of musculoskeletal recovery.

Rhea-AI Summary

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its first quarter fiscal year 2025 financial results announcement for May 6, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, where management will discuss the results and provide a business update.

Investors can participate by dialing 1-833-636-0497 and referencing the Bioventus Conference Call. A live webcast and accompanying materials will be available on the company's investor relations website, with replay access until May 5, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Bioventus (BVS) reported strong Q4 2024 results with revenue reaching $153.6 million, up 13.5% year-over-year, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company reduced its net loss from continuing operations to $0.3 million, compared to $7.7 million in the prior year.

Full-year 2024 revenue totaled $573.3 million, representing an 11.9% increase, with organic growth of 14.4%. Adjusted EBITDA from continuing operations grew 22.5% to $108.9 million. The company successfully divested its Advanced Rehabilitation Business for $24.7 million and reduced long-term debt by $48.3 million in Q4.

Looking ahead, Bioventus projects 2025 revenue between $560-570 million, representing organic growth of 6.1-8.0%, and expects Adjusted EBITDA of $112-116 million with improved margins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.29%
Tags
-
Rhea-AI Summary

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its fourth quarter fiscal year 2024 financial results announcement for March 11, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring management discussion of results and business updates.

Investors can participate by dialing 1-833-636-0497 and referring to the Bioventus Conference Call. A live webcast and accompanying materials will be available on the company's investor relations website, with replay access until March 10, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
conferences earnings
Rhea-AI Summary

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, announced that its CEO, Rob Claypoole, will present at the 43rd Annual J.P. Morgan Healthcare Conference.

The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). A live webcast, including a Q&A session, will be accessible on the Investors section of the Bioventus website. This webcast will be available until February 15, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
conferences
-
Rhea-AI Summary

Bioventus (BVS) has completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners, a private equity firm specializing in HealthTech companies. The transaction, which was initially announced on October 1, 2024, has generated approximately $20 million in net closing proceeds for Bioventus, enhancing the company's liquidity position. This strategic move allows Bioventus to sharpen its focus and improve execution within its core business segments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
Rhea-AI Summary

Bioventus (BVS) reported strong Q3 2024 financial results with revenue increasing 15.0% to $139.0 million. The company saw double-digit growth in Pain Treatments and Surgical Solutions. Net loss from continuing operations improved to $5.4 million compared to $8.8 million in the prior year. Adjusted EBITDA grew 8.4% to $23.6 million. The company raised its 2024 guidance, now expecting net sales of $562-567 million and reached an agreement to divest its Advanced Rehabilitation Business for up to $45.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.27%
Tags
Rhea-AI Summary

Bioventus (Nasdaq: BVS) has announced it will release its third quarter fiscal year 2024 financial results before market opening on Tuesday, November 5, 2024. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring management discussion of results and business updates. Investors can join via phone at 1-833-636-0497 or watch the live webcast on the company's investor relations website. The webcast recording will remain available for replay until November 4, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences earnings
-
Rhea-AI Summary

Bioventus Inc. (Nasdaq: BVS) has announced the sale of its Advanced Rehabilitation business, part of its Bioness subsidiary, to Accelmed Partners for $45 million. The deal includes $25 million in cash at closing and up to $20 million in potential earn-out payments. Bioventus expects to net approximately $20 million after fees and expenses, which will be used to repay existing debt.

The divestiture will reduce Bioventus's annual revenue by about $50 million and annual Adjusted EBITDA by approximately $6 million. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.

This strategic move allows Bioventus to focus on its core business and improve liquidity, while positioning the Advanced Rehabilitation business for growth under Accelmed's management. Moelis & Company and Reed Smith LLP are advising Bioventus on the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
Rhea-AI Summary

Bioventus Inc. (Nasdaq: BVS), a global leader in active healing innovations, has announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference. Mark Singleton, the company's senior vice president and chief financial officer, will engage in a fireside chat on Wednesday, August 14, 2024, at 9:00 a.m. ET.

The event will feature a live webcast of the presentation, followed by a question-and-answer session. Interested parties can access the webcast through the 'Investors' section of Bioventus' website at www.bioventus.com. The presentation will also be available for replay on the site after the event concludes, providing an opportunity for those unable to attend live to catch up on the company's insights and updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
conferences
Rhea-AI Summary

Bioventus (Nasdaq: BVS) reported strong Q2 2024 financial results, with revenue increasing 10.3% to $151.2 million and organic growth of 13.9%. The company saw double-digit growth in Pain Treatments and Surgical Solutions. Despite a net loss of $32.1 million due to a non-cash impairment charge, Adjusted EBITDA grew 22.4% to $34.5 million. Gross margin expanded by 350 basis points, and cash from operations increased 40.5% to $15.2 million.

Based on strong performance, Bioventus raised its full-year 2024 guidance, now expecting net sales of $557-567 million, Adjusted EBITDA of $104-107 million, and Non-GAAP EPS of $0.36-0.42. The company is focusing on executing strategic priorities, including potential divestiture of its Advanced Rehabilitation Business to reduce debt and focus on core operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.23%
Tags
Bioventus Inc.

Nasdaq:BVS

BVS Rankings

BVS Stock Data

517.35M
58.52M
11.45%
69.89%
1.21%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
DURHAM